$MD
Pediatrix Medical Group, Inc.

2018 Q3 Form 10-Q Financial Statement

#000119312518315785 Filed on November 01, 2018

View on sec.gov

Income Statement

Concept 2018 Q3
Revenue $896.7M
YoY Change 3.19%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $695.1M
YoY Change 1.05%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $28.71M
YoY Change 14.31%
% of Gross Profit
Operating Expenses $787.5M
YoY Change 6.06%
Operating Profit $109.2M
YoY Change -13.66%
Interest Expense $21.78M
YoY Change 18.2%
% of Operating Profit 19.95%
Other Income/Expense, Net -$18.71M
YoY Change 1.52%
Pretax Income $90.45M
YoY Change -16.25%
Income Tax $24.87M
% Of Pretax Income 27.5%
Net Earnings $65.58M
YoY Change -0.46%
Net Earnings / Revenue 7.31%
Basic Earnings Per Share $0.72
Diluted Earnings Per Share $0.72
COMMON SHARES
Basic Shares Outstanding 90.98M shares
Diluted Shares Outstanding 91.36M shares

Balance Sheet

Concept 2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $48.40M
YoY Change -18.52%
Cash & Equivalents $34.46M
Short-Term Investments $14.00M
Other Short-Term Assets $16.31M
YoY Change -73.09%
Inventory
Prepaid Expenses $17.84M
Receivables $522.8M
Other Receivables $0.00
Total Short-Term Assets $625.4M
YoY Change -4.27%
LONG-TERM ASSETS
Property, Plant & Equipment $137.8M
YoY Change 20.02%
Goodwill $4.303B
YoY Change 4.5%
Intangibles
YoY Change
Long-Term Investments $81.20M
YoY Change -1.34%
Other Assets $95.42M
YoY Change 39.04%
Total Long-Term Assets $5.213B
YoY Change 3.7%
TOTAL ASSETS
Total Short-Term Assets $625.4M
Total Long-Term Assets $5.213B
Total Assets $5.839B
YoY Change 2.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $30.71M
YoY Change 12.33%
Accrued Expenses $383.0M
YoY Change 2.13%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $500.0K
YoY Change -98.29%
Total Short-Term Liabilities $435.9M
YoY Change -8.41%
LONG-TERM LIABILITIES
Long-Term Debt $2.006B
YoY Change 11.62%
Other Long-Term Liabilities $40.94M
YoY Change -3.17%
Total Long-Term Liabilities $40.94M
YoY Change -3.17%
TOTAL LIABILITIES
Total Short-Term Liabilities $435.9M
Total Long-Term Liabilities $40.94M
Total Liabilities $2.823B
YoY Change 2.15%
SHAREHOLDERS EQUITY
Retained Earnings $2.016B
YoY Change 5.42%
Common Stock $999.6M
YoY Change -0.49%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.015B
YoY Change
Total Liabilities & Shareholders Equity $5.839B
YoY Change 2.78%

Cashflow Statement

Concept 2018 Q3
OPERATING ACTIVITIES
Net Income $65.58M
YoY Change -0.46%
Depreciation, Depletion And Amortization $28.71M
YoY Change 14.31%
Cash From Operating Activities $140.5M
YoY Change -29.71%
INVESTING ACTIVITIES
Capital Expenditures -$6.500M
YoY Change -35.64%
Acquisitions
YoY Change
Other Investing Activities -$2.300M
YoY Change -99.03%
Cash From Investing Activities -$8.800M
YoY Change -96.45%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -135.5M
YoY Change -343.27%
NET CHANGE
Cash From Operating Activities 140.5M
Cash From Investing Activities -8.800M
Cash From Financing Activities -135.5M
Net Change In Cash -3.800M
YoY Change -148.1%
FREE CASH FLOW
Cash From Operating Activities $140.5M
Capital Expenditures -$6.500M
Free Cash Flow $147.0M
YoY Change -30.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q3 us-gaap Business Combination Liabilities Arising From Contingencies Amount Recognized
BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized
24400000
CY2018Q3 us-gaap Cash Surrender Value Of Life Insurance
CashSurrenderValueOfLifeInsurance
16300000
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34461000
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
54461000
CY2018Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
413739000
CY2018Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
30709000
CY2018Q3 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
1903175000
CY2018Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
194457000
CY2018Q3 us-gaap Assets
Assets
5838724000
CY2017Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
48403000
CY2018Q3 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
500000000
CY2018Q3 us-gaap Assets Current
AssetsCurrent
625401000
CY2018Q3 us-gaap Assets Held For Sale Not Part Of Disposal Group
AssetsHeldForSaleNotPartOfDisposalGroup
46000000
CY2018Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
21667000
CY2018Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1380349000
CY2018Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
522826000
CY2018Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
998670000
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2018Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
89349000 shares
CY2018Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
89349000 shares
CY2018Q3 us-gaap Common Stock Value
CommonStockValue
893000
CY2018Q3 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
129637000
CY2018Q3 us-gaap Equity Method Investment Ownership Percentage
EquityMethodInvestmentOwnershipPercentage
0.490 pure
CY2018Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
595415000
CY2018Q3 us-gaap Goodwill
Goodwill
4303427000
CY2018Q3 us-gaap Held To Maturity Securities Current
HeldToMaturitySecuritiesCurrent
13965000
CY2018Q3 us-gaap Held To Maturity Securities Debt Maturities After Five Through Ten Years Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount
1000000
CY2018Q3 us-gaap Held To Maturity Securities Debt Maturities After One Through Five Years Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount
80226000
CY2018Q3 us-gaap Held To Maturity Securities Noncurrent
HeldToMaturitySecuritiesNoncurrent
81226000
CY2018Q3 us-gaap Interest Payable Current
InterestPayableCurrent
15418000
CY2018Q3 us-gaap Liabilities Current
LiabilitiesCurrent
435941000
CY2018Q3 us-gaap Liabilities
Liabilities
2823419000
CY2018Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5838724000
CY2018Q3 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
535000
CY2018Q3 us-gaap Malpractice Loss Contingency Accrual Undiscounted Current
MalpracticeLossContingencyAccrualUndiscountedCurrent
33468000
CY2018Q3 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
1264000000
CY2018Q3 us-gaap Malpractice Loss Contingency Accrual Undiscounted Noncurrent
MalpracticeLossContingencyAccrualUndiscountedNoncurrent
210942000
CY2018Q3 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
300000
CY2018Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
40046000
CY2018Q3 us-gaap Other Assets Current
OtherAssetsCurrent
16308000
CY2018Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
95423000
CY2018Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
17841000
CY2018Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
40941000
CY2018Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
137832000
CY2018Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2018Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
20000000
CY2018Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
2015742000
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
3015305000
CY2018Q3 md Accounts Payable And Accrued Liabilities Excluding Accrued Income Taxes Current
AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent
413739000
CY2018Q3 md Accrued Payroll Taxes And Benefits Current
AccruedPayrollTaxesAndBenefitsCurrent
78211000
CY2018Q3 md Long Term Debt And Capital Lease Obligations Excluding Long Term Line Of Credit
LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit
741958000
CY2018Q3 md Accrued Contingent Consideration Liability Current
AccruedContingentConsiderationLiabilityCurrent
21430000
CY2018Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
89420404 shares
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
55698000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
627235000
CY2017Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
92007000
CY2017Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1286035000
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
503999000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1017328000
CY2017Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
438017000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
34632000
CY2017Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
1790034000
CY2017Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
225429000
CY2017Q4 us-gaap Assets
Assets
5867278000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
2048189000
CY2017Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
20000000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
3066454000
CY2017Q4 us-gaap Malpractice Loss Contingency Accrual Undiscounted Current
MalpracticeLossContingencyAccrualUndiscountedCurrent
37912000
CY2017Q4 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
1110500000
CY2017Q4 us-gaap Malpractice Loss Contingency Accrual Undiscounted Noncurrent
MalpracticeLossContingencyAccrualUndiscountedNoncurrent
212274000
CY2017Q4 md Accounts Payable And Accrued Liabilities Excluding Accrued Income Taxes Current
AccountsPayableAndAccruedLiabilitiesExcludingAccruedIncomeTaxesCurrent
438017000
CY2017Q4 md Accrued Payroll Taxes And Benefits Current
AccruedPayrollTaxesAndBenefitsCurrent
75672000
CY2017Q4 us-gaap Business Combination Liabilities Arising From Contingencies Amount Recognized
BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized
30500000
CY2017Q4 us-gaap Cash Surrender Value Of Life Insurance
CashSurrenderValueOfLifeInsurance
15600000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
60200000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
80200000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
93721000 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
93721000 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
937000
CY2017Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
147797000
CY2017Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
639928000
CY2017Q4 us-gaap Goodwill
Goodwill
4283963000
CY2017Q4 us-gaap Held To Maturity Securities Current
HeldToMaturitySecuritiesCurrent
10292000
CY2017Q4 us-gaap Held To Maturity Securities Debt Maturities After Five Through Ten Years Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount
2121000
CY2017Q4 us-gaap Held To Maturity Securities Debt Maturities After One Through Five Years Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount
78561000
CY2017Q4 us-gaap Held To Maturity Securities Noncurrent
HeldToMaturitySecuritiesNoncurrent
80682000
CY2017Q4 us-gaap Interest Payable Current
InterestPayableCurrent
4495000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
531425000
CY2017Q4 us-gaap Liabilities
Liabilities
2800824000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5867278000
CY2017Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
1401000
CY2017Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
9200000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
53618000
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
37160000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
91934000
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
15584000
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
57905000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
123536000
CY2017Q4 md Long Term Debt And Capital Lease Obligations Excluding Long Term Line Of Credit
LongTermDebtAndCapitalLeaseObligationsExcludingLongTermLineOfCredit
740923000
CY2017Q4 md Accrued Contingent Consideration Liability Current
AccruedContingentConsiderationLiabilityCurrent
6259000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
22500000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
130000 shares
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-52293000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-387477000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
4078000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7295000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
16731000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
76465000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.98
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.00
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
308210000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
302080000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
1246000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
117811000
us-gaap Increase Decrease In Liability For Claims And Claims Adjustment Expense Reserve
IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve
8801000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-247000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-9798000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
25422000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
1650000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
9085000
us-gaap Interest Expense
InterestExpense
54715000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
784000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
666000 shares
us-gaap Investment Income Net
InvestmentIncomeNet
1176000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
64439000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
315743000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
2480000
us-gaap Operating Expenses
OperatingExpenses
2193119000
us-gaap Operating Income Loss
OperatingIncomeLoss
354373000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
24741000
us-gaap Payments To Acquire Other Property Plant And Equipment
PaymentsToAcquireOtherPropertyPlantAndEquipment
31976000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
70192000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
355084000
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
3825000
us-gaap Payment For Contingent Consideration Liability Operating Activities
PaymentForContingentConsiderationLiabilityOperatingActivities
574000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-3809000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
18684000
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
894000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
20515000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
1256000000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
1135500000
us-gaap Profit Loss
ProfitLoss
184269000
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
1622000
us-gaap Share Based Compensation
ShareBasedCompensation
22533000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
93014000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
92348000 shares
md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
88165000
md Practice Salaries And Benefits
PracticeSalariesAndBenefits
1720279000
md Percentage Of Net Patient Service Revenue By Type Of Payor
PercentageOfNetPatientServiceRevenueByTypeOfPayor
1.00 pure
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
29300000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
202000 shares
dei Amendment Flag
AmendmentFlag
false
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
3314000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-2500000
us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
24400000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-25739000
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-16928000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
81390000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
dei Document Type
DocumentType
10-Q
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-38135000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
1954000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.25
dei Entity Central Index Key
EntityCentralIndexKey
0000893949
dei Entity Registrant Name
EntityRegistrantName
MEDNAX, INC.
dei Entity Small Business
EntitySmallBusiness
false
dei Document Period End Date
DocumentPeriodEndDate
2018-09-30
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.26
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
319589000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
287469000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
4548000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
79054000
us-gaap Increase Decrease In Liability For Claims And Claims Adjustment Expense Reserve
IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve
-2608000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5351000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-70186000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
18827000
us-gaap Interest Expense
InterestExpense
63321000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-2427000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
521000 shares
us-gaap Investment Income Net
InvestmentIncomeNet
3968000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-54805000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-47780000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-140290000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
162331000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
3030000
us-gaap Operating Expenses
OperatingExpenses
2372153000
us-gaap Operating Income Loss
OperatingIncomeLoss
342274000
us-gaap Payments For Previous Acquisition
PaymentsForPreviousAcquisition
4600000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
15884000
us-gaap Payments To Acquire Other Property Plant And Equipment
PaymentsToAcquireOtherPropertyPlantAndEquipment
38135000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
302160000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
27035000
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
3869000
us-gaap Payment For Contingent Consideration Liability Operating Activities
PaymentForContingentConsiderationLiabilityOperatingActivities
686000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13252000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
10510000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
1364500000
us-gaap Proceeds From Sales Of Business Affiliate And Productive Assets
ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
22764000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
1211000000
us-gaap Profit Loss
ProfitLoss
208415000
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
1013000
us-gaap Share Based Compensation
ShareBasedCompensation
29344000
dei Trading Symbol
TradingSymbol
MD
us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
302200000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
92760000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
92239000 shares
md Payment For Purchase Consideration Related To Prior Period Acquisitions
PaymentForPurchaseConsiderationRelatedToPriorPeriodAcquisitions
1200000
CY2018Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
214000 shares
md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
92647000
md Increase Decrease In Accrued Payroll Taxes And Benefits
IncreaseDecreaseInAccruedPayrollTaxesAndBenefits
31000000
md Practice Salaries And Benefits
PracticeSalariesAndBenefits
1878527000
md Number Of Physician Group Practices Acquired
NumberOfPhysicianGroupPracticesAcquired
5 Company
md Number Of Pediatric Subspecialty Practices Acquired
NumberOfPediatricSubspecialtyPracticesAcquired
2 Company
md Number Of Radiology Practices Acquired
NumberOfRadiologyPracticesAcquired
2 Company
md Number Of Neonatology Practices Acquired
NumberOfNeonatologyPracticesAcquired
1 Company
md Percentage Of Net Patient Service Revenue By Type Of Payor
PercentageOfNetPatientServiceRevenueByTypeOfPayor
1.00 pure
CY2017Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7700000
CY2017Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
380000 shares
CY2017Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
25116000
CY2017Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.71
CY2017Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.71
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
101430000
CY2017Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
107999000
CY2017Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-240000
CY2017Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
42119000
CY2017Q3 us-gaap Interest Expense
InterestExpense
18428000
CY2017Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
292000 shares
CY2017Q3 us-gaap Investment Income Net
InvestmentIncomeNet
235000
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-18433000
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
742519000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
126432000
CY2017Q3 us-gaap Profit Loss
ProfitLoss
65880000
CY2017Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
92881000 shares
CY2017Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
92589000 shares
CY2017Q3 md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
29497000
CY2017Q3 md Practice Salaries And Benefits
PracticeSalariesAndBenefits
586476000
CY2017Q3 md Percentage Of Net Patient Service Revenue By Type Of Payor
PercentageOfNetPatientServiceRevenueByTypeOfPayor
1.00 pure
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8900000
CY2018Q3 md Percentage Of Net Patient Service Revenue By Type Of Payor
PercentageOfNetPatientServiceRevenueByTypeOfPayor
1.00 pure
CY2018Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
28709000
CY2018Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.72
CY2018Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.72
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
102905000
CY2018Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
90448000
CY2018Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
1766000
CY2018Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
24873000
CY2018Q3 us-gaap Interest Expense
InterestExpense
21782000
CY2018Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
375000 shares
CY2018Q3 us-gaap Investment Income Net
InvestmentIncomeNet
1302000
CY2018Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-18714000
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
787490000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
109162000
CY2018Q3 us-gaap Profit Loss
ProfitLoss
65575000
CY2018Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
91359000 shares
CY2018Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
90984000 shares
CY2018Q3 md Practice Supplies And Other Operating Expenses
PracticeSuppliesAndOtherOperatingExpenses
30159000
CY2018Q3 md Practice Salaries And Benefits
PracticeSalariesAndBenefits
625717000

Files In Submission

Name View Source Status
0001193125-18-315785-index-headers.html Edgar Link pending
0001193125-18-315785-index.html Edgar Link pending
0001193125-18-315785.txt Edgar Link pending
0001193125-18-315785-xbrl.zip Edgar Link pending
d613941d10q.htm Edgar Link pending
d613941dex101.htm Edgar Link pending
d613941dex311.htm Edgar Link pending
d613941dex312.htm Edgar Link pending
d613941dex32.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
md-20180930.xml Edgar Link completed
md-20180930.xsd Edgar Link pending
md-20180930_cal.xml Edgar Link unprocessable
md-20180930_def.xml Edgar Link unprocessable
md-20180930_lab.xml Edgar Link unprocessable
md-20180930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending